Divestment

Vivoryon Therapeutics

Development of drugs for Alzheimer's disease.

News

Key Facts

Sector: Life Sciences
Country: Germany
Fund: LSP 4
Entry: 2009
Exit: 2022
Website: Vivoryon Therapeutics

Vivoryon Therapeutics

News

September 30, 2025
EQT Life Sciences portfolio company Merus to be acquired by Genmab in an all-cash USD 8.0 billion transaction
September 16, 2025
EQT Life Sciences portfolio company VarmX partners with CSL in a strategic collaboration and option agreement worth up to USD 2.2 billion
June 11, 2025
EQT Life Sciences Co-Leads USD 135 Million Series B Financing in SpliceBio
June 9, 2025
EQT Life Sciences Leads USD 80 Million Series A Funding Round in Mosanna Therapeutics to Advance Sleep Apnea Nasal Spray

Do You Want to Know More?

We are eager to explore how we can achieve great things together.

Vivoryon Therapeutics | EQT Portfolio